Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Bonus Article A Fresh IPO That Long-Term Investors Shouldn't IgnoreWritten by Jordan Chussler. Article Published: 1/14/2026. 
In Brief - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is always a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a few of them offer considerable short-term upside potential. Of course, they also carry substantial downside risk. But even conservative investors who favor caution shouldn't overlook all recent IPOs—some may merit a place in buy-and-hold portfolios. If you missed out on gold's recent run…You've been given a second chance.
Because the gold market is moving to the next phase.
Something we call the Golden Paradox.
It's a hidden opportunity that's played out for nearly 100 years.
A way that could've helped investors make 31 times more …65 times more … Even 469 times more than just buying gold. To solve this Golden Paradox, click here One biotechnology company in the healthcare sector that recently went public could be an example. Last Year's IPO Success Stories Last year provides a strong illustration of why IPOs shouldn't be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have capitalized on its nearly 359% gain before the stock had been listed for 30 days, but longer-term holders have also enjoyed strong returns. Others, such as Medline (NASDAQ: MDLN), refute the misconception that IPOs are all high-risk startups. The medical products and services provider, which publicly debuted in December 2025, was founded in 1966 and already boasts a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it immediately attractive for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation, minimizing damage to healthy tissue compared with conventional radiation therapies. According to industry consultancy Grand View Research, the global nuclear medicine market, estimated at nearly $18 billion in 2024, is forecast to reach nearly $35 billion by 2030—a compound annual growth rate of 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the predominant player. Aktis Oncology's Clinical-Stage Biotechnology Wall Street expects biotech IPOs to rebound in 2026 after funding cuts by the Trump administration notably slowed healthcare listings in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised one of the largest sums for a biotech listing in recent memory. With $318 million in IPO proceeds, the firm now has a market cap of about $3.34 billion. According to the company's prospectus, its executive team includes experts in drug development, regulatory approval, and commercialization, with members of management having participated in bringing 14 currently FDA-approved products to market. Aktis develops targeted alpha radiopharmaceuticals, a class of precision oncology drugs using proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting significant strategic interest. Eli Lilly (NYSE: LLY) anchored its IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares in the offering. This builds on a 2024 partnership in which Lilly committed $60 million in cash and made an equity investment in Aktis to collaborate on tumor-targeting radiopharmaceuticals, with potential milestone payments exceeding $1 billion. The significance of Aktis's backing by Eli Lilly cannot be overstated. At roughly $1.01 trillion, Eli Lilly is one of the largest Big Pharma companies by market cap after reporting a near 109% year-over-year jump in net income from 2023 to 2024. That momentum is likely to continue when Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the recent $100 million in AKTS shares, the maker of Zepbound now has a sizable financial interest in the biotech startup's success.
| 
